Japanese med firm to open Lleida plant

Nipro said on May 18 it will move its current plant in Mollerussa, in Spain’s Lleida province, to a larger site in the city of Lleida and expand production of dialysis-treatment fluid there. The Japanese medical group plans to invest about 25 million euros in the project, according to Segre. The new facility will be built in the Torre Solé industrial estate and is due to begin operating in 2028, the newspaper reported. Nipro says on its corporate website that it is a global leader in renal care and dialysis-related treatment. ### Where is Nipro moving production from? Mollerussa is the site Nipro plans to leave as it shifts the operation to Lleida, Segre reported. The article said the company will relocate its existing plant in Mollerussa in order to enlarge output and make the new site one of its main European production centers for dialysis fluid. (segre.com) Nipro Renal Solutions Spain is already listed by the company as one of its Spanish operations. Nipro’s website identifies the business as part of Nipro Medical Europe and ties it to the group’s renal-care activities. ### What will the new Lleida plant make? Dialysis-treatment liquid is the product at the center of the expansion. (segre.com) Segre reported that Nipro wants the new Lleida installation to enlarge production capacity for that fluid and position the site among its main European manufacturing hubs for the product. (nipro-group.com) Renal care is one of Nipro’s core businesses globally. The company says it offers products and services for hemodialysis and related treatment, alongside other medical businesses. ### Why did Nipro pick Lleida? Segre said Nipro cited Lleida’s logistics connectivity and the availability of talent as reasons for choosing the new location. The report framed the move as an industrial expansion tied to the company’s need for a larger production base than the current Mollerussa site. (segre.com) (nipro-group.com) The Torre Solé industrial estate is the specific destination named in the report. That places the project in the city of Lleida rather than in Mollerussa, where the current plant operates. ### How large is the investment? Twenty-five million euros is the investment figure attached to the project in Segre’s report. (segre.com) The newspaper said the spending will fund the transfer from Mollerussa and the construction of the larger production plant in Lleida. Nipro has not, in the material reviewed on its corporate website, published a separate announcement with further details on jobs, construction timing or capacity figures. (segre.com) The company’s public site does describe Nipro as a multinational group focused on renal care, hospital supplies and other medical businesses. ### What happens next? The next dated milestone in the reporting is 2028, when the new Lleida plant is expected to enter service. (segre.com) Segre said that is when operations are due to start at the Torre Solé site after the transfer from Mollerussa. Until then, the clearest public markers are the planned investment amount, the named location in Lleida and the transfer of Nipro’s existing Mollerussa production base. (nipro-group.com) Those details come from Segre’s May 18 report and Nipro’s corporate description of its renal-care business in Spain and globally. (segre.com)